Borviz 2.5 Mg Injection

Description

About Borviz 2.5 mg Injection

Borviz 2.5 mg Injection contains 2.5 mg of bortezomib per vial, supplied as a single vial. Bortezomib is a proteasome inhibitor. Treatment is prescribed and supervised by a cancer specialist. It is given as an infusion by a doctor or nurse in a treatment centre, never self-administered.

How it works

Every cell disposes of unwanted proteins through a structure called the proteasome. Myeloma cells produce protein at an extreme rate and depend on that disposal route more than normal cells do. Bortezomib blocks the proteasome, so the proteins build up and the cell dies.

What it is used for

Bortezomib is used in multiple myeloma and in mantle cell lymphoma, usually in combination with other medicines.

Important: what this medicine is not

Bortezomib is not a medicine for nerve pain, epilepsy or any neurological condition. Nerve damage is in fact one of its side effects, not something it treats.

Safety and monitoring

Numbness, tingling, burning or pain in the hands and feet is the most characteristic effect and can limit treatment – report it early, because the dose can be adjusted before it becomes lasting. Platelet counts fall and recover within each cycle, so bleeding and bruising are monitored. Blood pressure can drop, causing dizziness on standing. Shingles is common enough that an antiviral is usually given alongside. Report breathlessness, swollen ankles or confusion.

Prescription and storage

A prescription from your healthcare provider is required to purchase bortezomib. Storage and handling follow the pack instructions and are managed by the treating centre.